- Home
- CHRS vs WIA Comparison
CHRS vs WIA Comparison
Compare CHRS & WIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- WIA
- Stock Information
- Founded
- CHRS 2010
- WIA 2003
- Country
- CHRS United States
- WIA United States
- Employees
- CHRS N/A
- WIA N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- WIA Trusts Except Educational Religious and Charitable
- Sector
- CHRS Health Care
- WIA Finance
- Exchange
- CHRS Nasdaq
- WIA Nasdaq
- Market Cap
- CHRS 191.3M
- WIA 186.8M
- IPO Year
- CHRS 2014
- WIA N/A
- Fundamental
- Price
- CHRS $1.47
- WIA $7.98
- Analyst Decision
- CHRS Strong Buy
- WIA
- Analyst Count
- CHRS 4
- WIA 0
- Target Price
- CHRS $5.38
- WIA N/A
- AVG Volume (30 Days)
- CHRS 2.3M
- WIA 39.2K
- Earning Date
- CHRS 11-06-2024
- WIA 01-01-0001
- Dividend Yield
- CHRS N/A
- WIA 12.29%
- EPS Growth
- CHRS N/A
- WIA N/A
- EPS
- CHRS N/A
- WIA N/A
- Revenue
- CHRS $304,340,000.00
- WIA N/A
- Revenue This Year
- CHRS $2.47
- WIA N/A
- Revenue Next Year
- CHRS N/A
- WIA N/A
- P/E Ratio
- CHRS N/A
- WIA N/A
- Revenue Growth
- CHRS 44.19
- WIA N/A
- 52 Week Low
- CHRS $0.66
- WIA $7.56
- 52 Week High
- CHRS $2.97
- WIA $8.91
- Technical
- Relative Strength Index (RSI)
- CHRS 50.55
- WIA 37.43
- Support Level
- CHRS $1.35
- WIA $7.94
- Resistance Level
- CHRS $1.77
- WIA $8.05
- Average True Range (ATR)
- CHRS 0.13
- WIA 0.06
- MACD
- CHRS -0.02
- WIA 0.00
- Stochastic Oscillator
- CHRS 28.57
- WIA 32.14
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About WIA Western Asset Inflation-Linked Income Fund
Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation.